Christopher Kroeger Sells 34,411 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) CEO Christopher Kroeger sold 34,411 shares of Maplight Therapeutics stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $27.69, for a total value of $952,840.59. Following the completion of the transaction, the chief executive officer directly owned 1,526,309 shares in the company, valued at approximately $42,263,496.21. This represents a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maplight Therapeutics Trading Up 9.8%

Shares of Maplight Therapeutics stock traded up $2.69 during midday trading on Monday, reaching $30.09. The company had a trading volume of 288,241 shares, compared to its average volume of 312,441. The stock’s fifty day moving average is $23.27. The stock has a market capitalization of $1.28 billion and a price-to-earnings ratio of -0.76. Maplight Therapeutics, Inc. has a fifty-two week low of $12.24 and a fifty-two week high of $33.28.

Maplight Therapeutics (NASDAQ:MPLT) last announced its earnings results on Thursday, March 26th. The company reported ($2.47) EPS for the quarter, missing the consensus estimate of ($1.05) by ($1.42). Research analysts forecast that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Fcpm Iii Services B.V. acquired a new position in Maplight Therapeutics during the 4th quarter worth approximately $56,672,000. T. Rowe Price Investment Management Inc. acquired a new position in Maplight Therapeutics during the 4th quarter worth approximately $49,154,000. Goldman Sachs Group Inc. acquired a new position in Maplight Therapeutics during the 4th quarter worth approximately $34,026,000. Nan Fung Group Holdings Ltd acquired a new position in Maplight Therapeutics during the 4th quarter worth approximately $17,060,000. Finally, 5AM Venture Management LLC acquired a new position in Maplight Therapeutics during the 4th quarter worth approximately $16,687,000.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. TD Cowen assumed coverage on Maplight Therapeutics in a research report on Tuesday, April 7th. They set a “buy” rating on the stock. Weiss Ratings assumed coverage on Maplight Therapeutics in a research report on Thursday, January 22nd. They set a “sell (e)” rating on the stock. HC Wainwright assumed coverage on Maplight Therapeutics in a research report on Monday, May 4th. They set a “buy” rating and a $45.00 target price on the stock. Needham & Company LLC assumed coverage on Maplight Therapeutics in a research report on Wednesday, April 8th. They set a “buy” rating and a $37.00 target price on the stock. Finally, Canaccord Genuity Group assumed coverage on Maplight Therapeutics in a research report on Thursday, March 19th. They set a “buy” rating and a $35.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $34.43.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.